However, the above strategies have rarely efficient antitumor activity in HCC and the reasons are complicated, including promoted interaction of EGFR with mTORC2, cross-talk between EGFR families and the complex signaling pathways [7]. The gene discussed is EGFR; the disease is hepatocellular carcinoma.